Spyre Therapeutics, Inc. (SYRE) company profile
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
About Spyre Therapeutics
Pharmaceutical Preparations, SIC 2834
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company that creates long-acting monoclonal antibodies and combination therapies to treat inflammatory bowel disease and rheumatic conditions. Its drug development pipeline targets biological pathways including α4β7, TL1A, and IL-23, which are being advanced as individual therapies as well as fixed-dose pairwise combinations. The company focuses on conditions such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Because its product candidates remain in clinical evaluation, Spyre does not currently sell commercial products, though its prospective end-users are individuals suffering from these chronic immune-mediated disorders.
The company operates with 102 full-time employees and does not own or run its own manufacturing, testing, storage, or distribution facilities. Instead, it relies entirely on third-party contract facilities and external service providers across the United States and internationally, including China, while establishing additional domestic supplier redundancies. The provided text details operations across these clinical and manufacturing partners, but it does not specify the location of the company's corporate headquarters.
Summary of the business section of Spyre Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Spyre Therapeutics, Inc.
- Founded
- 2013
- Headquarters
- Waltham, MA
- Address
- 221 Crescent Street, Building 23, Suite 105 02453
- Phone
- (617) 651-5940
- Website
- aegleabio.com
- Employees
- 102, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- SYRE
- Former tickers
- AGLE until Nov 28, 2023
- Exchange
- Nasdaq
- IPO date
- Apr 7, 2016
- Shares outstanding
- 88M, Jul 28, 2026
- Public float
- $1.10B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-25 reverse, Sep 8, 2023
- SEC CIK
- 1636282
- CUSIP
- 00773J202
- ISIN
- US00773J2024
- FIGI
- BBG0067L94B2
- Share class FIGI
- BBG0067L94C1
- LEI
- 52990017AIJPRH3HQH40
- EIN
- 46-4312787
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Cameron Turtle | Chief Executive Officer, Director | 537,540 |
| Scott L. Burrows | Chief Financial Officer | 79,762 |
| Heidy King-Jones | See Remarks | 2,845 |
| Sheldon Sloan | Chief Medical Officer | 8,334 |
| Jeffrey W. Albers | Director | 9,360 |
| Michael Thomas Henderson | Director | 68,606 |
| Healthcare Fund II L.P. Fairmount | Director | 1,190,497 |
| Tomas Kiselak | Director | 9,460,540 |
| Funds Management LLC Fairmount | Director | 812,076 |
| Peter Evan Harwin | Director | 4,830,177 |
| Mark C. McKenna | Director | – |
| Laurie Stelzer | Director | – |
| Sandra Milligan | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $6.71M | $13.87M | $2.20M | $17 | $125 |
| FY2024 | $6.96M | $14.29M | $5.80M | $12 | $93 |
| FY2023 Cameron Turtle | $15.92M | $48.71M | $7.07M | $11 | $94 |
| FY2023 Jeffrey M.Goldberg | $830.21K | $122.21K | $7.07M | $11 | $94 |
| FY2023 Jonathan Alspaugh | $8.36M | $13.59M | $7.07M | $11 | $94 |
| FY2022 | $2.39M | $431.09K | $1.05M | $6 | $90 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Cameron Turtle Chief Executive Officer | $665.00K | $5.55M | $475.48K | $14.00K | $6.71M | -4% |
| Scott Burrows Chief Financial Officer | $490.00K | $1.43M | $254.80K | $14.00K | $2.19M | -1% |
| Sheldon Sloan Chief Medical Officer | $503.00K | $1.43M | $261.56K | $14.00K | $2.21M | -76% |
| Heidy King-Jones Chief Legal Officer and Corporate Secretary | $490.00K | $1.43M | $254.80K | $14.00K | $2.19M | +7% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 7, 2016
- Offer price
- $10.00
- Securities offered
- 5,000,000
- Gross proceeds
- $50.00M
- Exchange
- Nasdaq
- First trading day
- Apr 7, 2016
- First-day close
- $9.77-2.3%
- Lock-up ends (est.)
- Oct 4, 2016
“We have been approved to list our common stock on The NASDAQ Global Market under the symbol “AGLE.” The public offering price is $10.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 102 employees, all of whom were employed full time.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?